Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL
Policy / Regulatory

Insurance Association of China Unveils First Commercial Insurance Recommended Drug List – 58 Drugs and Devices, Nearly 60% Outside the NRDL

The Insurance Association of China (IAC) released a recommended drug list for commercial insurance, selecting an initial batch of 58 recommended drugs and medical devices. The list targets coverage gaps…

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
CompanyDrug

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Bio‑Thera's BAT2306 Becomes World's First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis
CompanyDrug

Bio‑Thera’s BAT2306 Becomes World’s First Secukinumab Biosimilar with NMPA Approval Across Psoriasis, Ankylosing Spondylitis and Psoriatic Arthritis

TYK Medicines' Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI
CompanyDrug

TYK Medicines’ Asandeutertinib (TY‑9591) Set to Ship First Commercial Batch – Qilu Pharmaceutical to Launch China Sales of the NMPA‑Approved EGFR‑TKI

Abbisko's PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor
CompanyDrug

Abbisko’s PIMJETMI (Pimicotinib) Wins FDA Approval for Symptomatic Tenosynovial Giant Cell Tumor – First U.S. Green Light for the China‑Born CSF‑1R Inhibitor

Evopoint Biosciences' Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP
CompanyDrug

Evopoint Biosciences’ Imipenem/Cilastatin/Funobactam Wins NMPA Marketing Approval – Class 1 Triple‑Combination Antibiotic for HABP and VABP

Eli Lilly's Foundayo (Orforglipron) Wins NMPA Approval – First Oral GLP‑1 Receptor Agonist for Adult Weight Management in China
CompanyDrug

Eli Lilly’s Foundayo (Orforglipron) Wins NMPA Approval – First Oral GLP‑1 Receptor Agonist for Adult Weight Management in China

JW Therapeutics Transfers Greater China and ASEAN Rights in Solid Tumor Cell Therapy Programs to Eureka – Deal Includes GPC3 and AFP‑Targeted TCR‑T Candidates

JW Therapeutics Transfers Greater China and ASEAN Rights in Solid Tumor Cell Therapy Programs to Eureka – Deal Includes GPC3 and AFP‑Targeted TCR‑T Candidates

JW Therapeutics (HKG: 2126) announced that it has entered into a license and transfer agreement with Eureka Therapeutics and its affiliates covering Greater China and ASEAN regional rights to certain solid tumor cell therapy projects previously acquired by the company,…

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB
CompanyDeals

Fuzhou Luyan Pharmacy Secures Exclusive Greater China Rights to French Synergia Brand in Strategic Partnership with Curae LAB

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout
CompanyDeals

Hangzhou Eli Radiopharma Closes Nearly RMB 400 Million Series A Round – Capital Earmarked for Radiopharmaceutical Pipeline and Radiotheranostic Platform Buildout

Amgen's Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren's Disease Activity
CompanyDrug

Amgen’s Dazodalibep Hits Phase 3 Milestone in OASIZ‑301 – First Trial to Show Clinically Meaningful Improvement in Systemic Sjögren’s Disease Activity

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class
CompanyDrug

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

Revvity and BioMap Sign Strategic AI4S Partnership – A "Dry‑Wet" Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences
CompanyDeals

Revvity and BioMap Sign Strategic AI4S Partnership – A “Dry‑Wet” Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit
CompanyDeals

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

AstraZeneca plc (NYSE: AZN) has completed the acquisition of Omniose, a vaccine bioconjugation specialist, securing technology and expertise that could strengthen its efforts to protect people from bacterial threats. With…

MindRank and BoomRay Forge Strategic Alliance to Build AI‑Driven Radioligand Conjugates – Cyclic Peptide RDCs Target First‑in‑Class Oncology Assets
CompanyDeals

MindRank and BoomRay Forge Strategic Alliance to Build AI‑Driven Radioligand Conjugates – Cyclic Peptide RDCs Target First‑in‑Class Oncology Assets

Charles River to Acquire Frontage's Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania
CompanyDeals

Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania

Visen Pharmaceuticals Designates Distinct HealthCare as Skytrofa Partner Institution at CIIE – Expanding Weekly Long‑Acting Growth Hormone Into China's Private Healthcare Channel
CompanyDeals

Visen Pharmaceuticals Designates Distinct HealthCare as Skytrofa Partner Institution at CIIE – Expanding Weekly Long‑Acting Growth Hormone Into China’s Private Healthcare Channel

RemeGen Licenses Global Rights to Rongchang's Pan‑RAS(ON) Inhibitor RCZY‑690 – Deal Value up to RMB 4.87 Billion
CompanyDeals

RemeGen Licenses Global Rights to Rongchang’s Pan‑RAS(ON) Inhibitor RCZY‑690 – Deal Value up to RMB 4.87 Billion

- Advertisement -
RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus
CompanyDeals

RonGu Biotechnology Completes Series A Financing of Nearly RMB 100 Million – Advancing Off‑the‑Shelf CAR‑NK and CAR‑T Therapies for Systemic Lupus Erythematosus

Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform
CompanyDeals

Sanyou Biopharmaceuticals Completes Series C Financing of Nearly RMB 100 Million – Zero2IPO Industry Investment Fund Backs AI‑Driven Drug Discovery Platform

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…

China Issues Joint Notice to Accelerate Hospital Adoption of Innovative Drugs – NRDL and Commercial Insurance Lists Get Fast-Track Deployment
Policy / Regulatory

China Issues Joint Notice to Accelerate Hospital Adoption of Innovative Drugs – NRDL and Commercial Insurance Lists Get Fast-Track Deployment

CDE Opens Public Comment on 112th Draft Batch of Reference Preparations Catalogue for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 112th Draft Batch of Reference Preparations Catalogue for Chemical Generic Drugs

China's NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape
Policy / Regulatory

China’s NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

More News

Pfizer and Blackstone Life Sciences Strike USD 1.5 Billion Co‑Funding Deal for Berobenatide – Potential First‑in‑Class Monthly GLP‑1 for Obesity
Others

Pfizer and Blackstone Life Sciences Strike USD 1.5 Billion Co‑Funding Deal for Berobenatide – Potential First‑in‑Class Monthly GLP‑1 for Obesity

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia
CompanyDrug

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Hengrui Wins NMPA Trial Clearances for Two Assets – SHR‑1139 Bispecific Antibody and First‑of‑Kind Oral Lp(a) Inhibitor HRS‑5346
CompanyDrug

Hengrui Wins NMPA Trial Clearances for Two Assets – SHR‑1139 Bispecific Antibody and First‑of‑Kind Oral Lp(a) Inhibitor HRS‑5346

FDA Approves Bayer's Sunharbo (Asundexian) – World's First FXIa Inhibitor for Secondary Stroke Prevention
CompanyDrug

FDA Approves Bayer’s Sunharbo (Asundexian) – World’s First FXIa Inhibitor for Secondary Stroke Prevention

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia
CompanyDrug

Ribo Life Science Files EU Phase I CTA for SR122 – Dual‑Targeting ApoC3/PCSK9 siRNA Advancing Into Europe for Dyslipidemia

Henlius and Organon's HLX11 Approved in Brazil – First Pertuzumab Biosimilar Cleared by Anvisa for HER2‑Positive Breast Cancer
CompanyDrug

Henlius and Organon’s HLX11 Approved in Brazil – First Pertuzumab Biosimilar Cleared by Anvisa for HER2‑Positive Breast Cancer

WuXi AppTec Removed From DoD 1260H Chinese Military Companies List – Legal Challenge Ends Adverse Designation
Legal / IP

WuXi AppTec Removed From DoD 1260H Chinese Military Companies List – Legal Challenge Ends Adverse Designation

Novo Nordisk Wins CNIPA Patent Term Extension for Ozempic – CKD Indication Exclusivity in China Extended to March 2031
CompanyDrug

Novo Nordisk Wins CNIPA Patent Term Extension for Ozempic – CKD Indication Exclusivity in China Extended to March 2031

Show More